242 related articles for article (PubMed ID: 32923909)
1. Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy.
Li S; Lai H; Liu J; Liu Y; Jin L; Li Y; Liu F; Gong Y; Guan Y; Yi X; Shi Q; Cai Z; Li Q; Li Y; Zhu M; Wang J; Yang Y; Wei W; Yin D; Song E; Liu Q
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923909
[TBL] [Abstract][Full Text] [Related]
2. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract][Full Text] [Related]
3. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy.
Kim JY; Park D; Son DS; Nam SJ; Kim SW; Jung HH; Kim YJ; Park G; Park WY; Lee JE; Park YH
Oncotarget; 2017 Oct; 8(49):86423-86434. PubMed ID: 29156805
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
[TBL] [Abstract][Full Text] [Related]
7. Prospective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.
Shah D; Wells A; Cox M; Dawravoo K; Abad J; D'Souza A; Suh G; Bayer R; Chaudhry S; Zhang Q; Cristofanilli M; Bentrem D; Chawla A
Ann Surg; 2024 Jan; ():. PubMed ID: 38258582
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Cavallone L; Aguilar-Mahecha A; Lafleur J; Brousse S; Aldamry M; Roseshter T; Lan C; Alirezaie N; Bareke E; Majewski J; Ferrario C; Hassan S; Discepola F; Seguin C; Mihalcioiu C; Marcus EA; Robidoux A; Roy JA; Pelmus M; Basik M
Sci Rep; 2020 Sep; 10(1):14704. PubMed ID: 32895401
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.
Butler TM; Boniface CT; Johnson-Camacho K; Tabatabaei S; Melendez D; Kelley T; Gray J; Corless CL; Spellman PT
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833418
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
[TBL] [Abstract][Full Text] [Related]
11. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy.
Wang R; Wang B; Zhang H; Liao X; Shi B; Zhou Y; Zhou C; Yan Y; Zhang W; Wang K; Ge G; Ren Y; Tang X; Gan B; He J; Niu L
Breast; 2024 Apr; 76():103738. PubMed ID: 38685149
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
Front Oncol; 2021; 11():736769. PubMed ID: 34868925
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy.
Kitahata Y; Kawai M; Hirono S; Okada KI; Miyazawa M; Motobayashi H; Ueno M; Hayami S; Miyamoto A; Yamaue H
Ann Surg Oncol; 2022 Mar; 29(3):1596-1605. PubMed ID: 34724126
[TBL] [Abstract][Full Text] [Related]
14. Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.
Ciriaco N; Zamora E; Escrivá-de-Romaní S; Miranda Gómez I; Jiménez Flores J; Saura C; Sloane H; Starus A; Fredebohm J; Georgieva L; Speight G; Jones F; Ramón Y Cajal S; Espinosa-Bravo M; Peg V
Ther Adv Med Oncol; 2022; 14():17588359221139601. PubMed ID: 36479470
[TBL] [Abstract][Full Text] [Related]
15. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
[TBL] [Abstract][Full Text] [Related]
16. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.
Lv J; Wu C; Li J; Chen F; He S; He Q; Zhou G; Ma J; Sun Y; Wei D; Lin L
BMC Med; 2022 Aug; 20(1):268. PubMed ID: 35996151
[TBL] [Abstract][Full Text] [Related]
17. Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients.
Sharbatoghli M; Fattahi F; Aboulkheyr Es H; Akbari A; Akhavan S; Ebrahimi M; Asadi-Lari M; Totonchi M; Madjd Z
Front Genet; 2022; 13():938985. PubMed ID: 35938032
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Magbanua MJM; Li W; Wolf DM; Yau C; Hirst GL; Swigart LB; Newitt DC; Gibbs J; Delson AL; Kalashnikova E; Aleshin A; Zimmermann B; Chien AJ; Tripathy D; Esserman L; Hylton N; van 't Veer L
NPJ Breast Cancer; 2021 Mar; 7(1):32. PubMed ID: 33767190
[TBL] [Abstract][Full Text] [Related]
19. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
20. Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.
Cai G; Guan Z; Jin Y; Su Z; Chen X; Liu Q; Wang C; Yin X; Zhang L; Ye G; Luo W
JCO Precis Oncol; 2022 Jan; 6():e2100120. PubMed ID: 35025620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
